Boceprevir and Telaprevir for the Treatment of Hepatitis C

[Guest guest]

clinical care options

Having trouble reading this email, click here to view in your browser.

CME/CE-Certified Module

September 28, 2011

A Practical Guide for the Use of Boceprevir and Telaprevir for the Treatment of

Hepatitis C

In this expert consensus module, 7 world-renowned HCV experts, Nezam H.

Afdhal, MD, FRCPI; Geoffrey M. Dusheiko, MD, FCP(SA), FRCP; Xavier Forns, MD;

Ira M. son, MD; M. Jensen, MD; Jean-Michel Pawlotsky, MD, PhD; and

Fred Poordad, MD, provide guidance on the use of boceprevir and telaprevir in

the treatment of chronic hepatitis C.

Topics covered include:

Selecting Candidates for Treatment With Telaprevir or Boceprevir

Predictors of Response and Early Viral Kinetics

Selecting a Treatment Regimen

On-Treatment Management: Futility Rules and Prevention of Resistance

Managing Adverse Events With PI-Based Therapy

Considerations for Special Patient Populations

To download the accompanying slideset for use in your own noncommercial

presentations,

click here.

The Future of HCV Therapy With the Advent of Direct-Acting Antiviral

Agents

http://clinicaloptions.com/Hepatitis/Treatment%20Updates/HCV%20New%20Agents.aspx

Hepatitis Slide

Library

Review hundreds

of slidesets featuring

the latest hepatitis

treatment data. Then download PowerPoint files for use in your own

noncommercial talks. Click here to start.

HCV

FIND THE ANSWERS AT INPRACTICE.COM

Physicians Jointly sponsored by Annenberg Center for Health Sciences at

Eisenhower and Clinical Care Options, LLC.

Nurses: Nursing contact hours provided through the coprovidership of

Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options,

LLC.

Annenberg Center for Health Sciences at Eisenhower is accredited as a

provider of continuing nursing education by the American Nurses Credentialing

Center's Commission on Accreditation.

Release date: September 15, 2011

Expiration date: September 14, 2012

This program is supported by educational grants from Janssen

Therapeutics, Merck, and Vertex.

Topics

Fibrosis and Cirrhosis

HIV Coinfection

HBV

Nash, ALD, etc

HCV

Other Hepatitis Viruses

Hepatocellular Carcinoma

Transplantation

Resources

Live Events

Expert Viewpoints

Bookstore

Slideset Downloads

Interactive Tools

Webcasts

Podcasts

Guidelines

Conference Coverage

CME Programs

Slidesets

Cases/a>

Live Events

Bookstore

Resources

Site Map

RSS

Contact Us

Help

Site Requirements

Terms of Use

Privacy Policy

HIV Site Tour

To ensure you receive Clinical Care Options educational materials by

email,

please add info@... to your contacts or address book.

Not

a member yet? Click here |